Edition:
United Kingdom

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

2.82USD
5:35pm BST
Change (% chg)

$0.16 (+6.02%)
Prev Close
$2.66
Open
$2.67
Day's High
$2.83
Day's Low
$2.67
Volume
128,586
Avg. Vol
283,727
52-wk High
$3.86
52-wk Low
$1.55

About

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $357.13
Shares Outstanding(Mil.): 134.26
Dividend: --
Yield (%): --

Financials

  AGEN.OQ Industry Sector
P/E (TTM): -- 103.12 37.45
EPS (TTM): -0.80 -- --
ROI: -74.03 7.69 12.16
ROE: -- 8.19 16.93

Agenus shares soar after cancer therapy deal with Gilead

Shares of Agenus Inc surged as much as 70 percent on Thursday after the company said it would develop and market up to five of its immuno-oncology therapies in partnership with Gilead Sciences Inc.

20 Dec 2018

UPDATE 1-Agenus shares soar after cancer therapy deal with Gilead

Dec 20 Shares of Agenus Inc surged as much as 70 percent on Thursday after the company said it would develop and market up to five of its immuno-oncology therapies in partnership with Gilead Sciences Inc.

20 Dec 2018

Gilead, Agenus sign deal to develop immuno-oncology therapies

Dec 20 Gilead Sciences Inc has inked a collaboration agreement with Agenus Inc for the development and marketing of up to five novel immuno-oncology therapies.

20 Dec 2018

Earnings vs. Estimates